Centessa Pharmaceuticals: Smooth Move To New Programs, But Questions Remain
Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...
Zacks Investment Research on MSN2 天
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680
Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and ...
Clinical Trials Arena2 天
Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...
Investor's Business Daily on MSN3 天
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.
Alkermes initiates Phase 2 study evaluating ALKS 2680 in idopathic hypersomnia
Alkermes (ALKS) announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to ...
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the ...
Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...